Medtronic Infection Control technology – based on inventions by Joachim Kohn, PhD, surrounding unique biodegradable polymer technology (i.e., tyrosine-derived polyarylates) – has received a world-wide license from Rutgers, The State University of New Jersey, which covers a broad range of absorbable materials and drug delivery technology. Additionally, Medtronic Infection Control has licensed from Baylor College of Medicine and The University of Texas MD Anderson Cancer Center combination drug patents and associated technologies to address the problem of postsurgical infection and fibrosis. Medtronic Infection Control is deploying its capabilities across a broad range of combination medical products and currently holds more than 70 foreign and domestic patents that permit the design, synthesis, and use of thousands of unique absorbable polymers.
The technology used in the TYRX™ product line:
- Is easily manipulated for a wide variety of end-use applications from microspheres and gels to coatings and partially load-bearing plastics
- Contains multiple hydrogen bonding sites that promote long-term drug elution and little or no "burst" effect
- Degrades in a relatively linear fashion and as a result, has minimal acidity, and is much less likely to promote inflammation and scarring
TYRX™ has a unique family of tyrosine-based bioabsorbable polymers that can be tailored or "tuned" to:
- Elute single or multiple drugs
- Elute drugs at a controllable rate and time
- Absorb at a predetermined rate, and
- Possess a wide variety of mechanical properties
TYRX™ tyrosine-based bioabsorbable polymers are designed to degrade to natural metabolites or substances with known safety history:
- Absorb benignly in vivo
- Elicit minimal inflammatory response, and have been employed in FDA-cleared implantable medical devices
There is a strong clinical rationale behind the combination of minocycline and rifampin selected for the TYRX™ Antibacterial Envelopes and future TYRX™ antibacterial products. Minocycline and rifampin have been shown to provide a broad spectrum of activity against a wide range of antibiotic-sensitive and antibiotic-resistant bacteria, including methicillin- and vancomycin-resistant strains.
In addition, the results from five Randomized Clinical Trials (RCTs) have demonstrated that minocycline and rifampin coatings help reduce medical device implant infections.
In vitro testing1,2 with central venous catheters has demonstrated that the combination of minocycline and rifampin is safe, effective, and:
- Superior to a combination of chlorhexidine and silver sulfadiazine
- Superior to vancomycin, clindamycin, novobiocin, and minocycline alone, and
- Equivalent to ceftazidime or amphotericin B against gram-negative bacilli and Candida albicans
Additionally, in in vitro, the absorbable antibacterial envelope demonstrated antimicrobial activity against Staphylococcus aureus, methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Staphylococcus lugdunensis, Escherichia coli, and Acinetobacter baumannii, which represent a majority of the pathogens reported in vagus nerve stimulator, deep brain stimulator, spinal cord neuromodulator, or sacral nerve stimulator infections.
- Hanna H et al. J Clin Oncol. 2004;22(15):3163-3171.
- Leon C et al. Intensive Care Med. 2004;30(10):1891-1899.
- Zabramski JM et al. J Neurosurg.2003;98(4):725-730.
- Chatzinikolaou I et al. Am J Med.2003;115(5):352-357.
- Raad I et al. Ann Intern Med. 1997;128(4):267-274.
PATHOGENS & PROPHYLAXIS CLINICAL DATA
CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED) INFECTIONS CONTINUE TO OCCUR AND CAN BE LIFE THREATENING.
Update on CIED infections and their management: a scientific statement from the American Heart Association, endorsed by the Heart Rhythm Society.1
CURRENT ANTIBIOTIC PROPHYLAXIS FALLING SHORT
- Cefazolin and vancomycin can have important clinical limitations when used as a single agent to reduce CIED infection.6-11
- Coagulase(-) Staphylococcus species and S aureus are responsible for ~70% of CIED infections and are increasingly resistant to methicillin.1-7
*Data from blood cultures
- Baddour LM et al. Circulation.2010;121(3):458-477.
- Lekkerkerker JC et al. Heart.2009;95(9):715-720
- de Oliveira JC et al. Circ Arrhyth Electrophysiol.2009;2(1):29-34.
- Da Costa A et al. Circulation. 1998;97(18): 1791-1795.
- Chua J et al.Ann Intern Med. 2000;133(8):604-608.
- Wisplinghoff H et al CID. 2004;39(3):309-317
- NNIS System Report. Am J Infect Control 2004;32(8):470-485.
- Klug D et al. Circulation. 2007;116(12):1349-1355.
- Gilbert DN et al.The Sanford Guide to Antimicrobial Therapy 39th ed. 2012: Antimicrobial Therapy Inc.; Hyde Park, VT.
- Tarakji et al. Heart Rhythm. 2010;7(8):1043-1047.
- Kachroo et al. Ann Pharmacother. 2006;40(3):381.
MORE ANTIBACTERIAL COVERAGE WHEN ADDED TO SINGLE-AGENT THERAPIES
The TYRX™ Absorbable Antibacterial Envelope and the original TYRX™ Antibacterial Envelope have identical antibiotic efficacy for the pathogens listed above.
The amount of drug dose contained in the TYRX™ Antibacterial Envelope is <10% of the recommended daily oral dose of minocycline and rifampin.1
Cefazolin and vancomycin are infrequently used in combination.
- Substantial overlap (both have activity against gram (+) organisms).1
- Neither has strong profile against gram (-) organisms.
- The Sanford Guide to Antimicrobial Therapy. Web Edition. 2015: Antimicrobial Therapy Inc.; Hyde Park, VT.
- Zinner SH et al. J Infect Dis. 1981;144(4):365-371.
- Darouiche RO et al. Int J Antimicrob Agents. 1995;6(1):31-36.
- Segreti J et al. Diagn Microbiol Infect Dis. 1989;12(3):253-255.
- Lansdown A et al. Issues in Toxicology. 2010; 5.3:123.
- Percival SL et al. Wound Repair Regeneration. 2011; 19(6); 769-770. Online publication.
- Argentum Medical. Silverlon® Product Brochure.
- Townsend Letter for Doctors & Patients. April 2006; Issue 273: 66-72.